Indication: Tolvaptan (Jynarque )is a selective vasopressin V2-receptor antagonist indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease. It is also used to treat hyponatremia in patients with heart failure or syndrome of inappropriate antidiuretic hormone.

Insight:

Dosing: May range from 15 mg to 120 mg, based on the initial titration or target dosage.
Dosage forms: Tablets 15 mg, 30 mg, 45 mg, 60 mg and 90 mg .
Adverse events: Most common observed adverse reactions with tolvaptan (incidence >10% and at least twice that for placebo) were thirst, polyuria, nocturia, pollakiuria, and polydipsia.
Mechanism of action: Tolvaptan is a selective vasopressin V2-receptor antagonist with an affinity for the V2-receptor that is 1.8 times that of native arginine vasopressin.

Source: JYNARQUE-PI (otsuka-us.com)